IP Library Granted Patent US 12,409,441
Granted Patent B2
US 12,409,441 · App. 17/800,515 · Granted Sep 9, 2025

Method of preparing polymer-filled chromatography resin

Inventors: James Wei Xu (Basking Ridge, NJ); Jiali Liao (San Ramon, CA); Christopher Belisle (Walnut Creek, CA); Fang Song (Wuxi, CN); Haihui Yuan (Nantong, CN); Juan You (Wuxi, CN); Wenli Cao (Wuxi, CN); Xiaozhong Bao (Wuxi, CN)
Assignee: Bio-Rad Laboratories, Inc.
B01J20/3204B01J20/286B01J20/3057B01J2220/86
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,409,441
App. No.
17/800,515
Granted
Sep 9, 2025
Kind
B2
Abstract

Methods of preparing polymer-filled chromatography resin and their uses are provided.

Claims (26)

1. A method of preparing a polymer-filled chromatography resin, the method comprising:

adding a chromatography resin to a solution comprising melted polymer while stirring to allow the melted polymer to absorb or otherwise enter the pores of the chromatography resin;

atomizing the solution and collecting insoluble porous polymer-filled chromatography resin beads in a water bath; and

removing excess polymer from the insoluble porous polymer-filled chromatography resin beads.

2. The method of claim 1 , wherein the removing step comprises passing the insoluble porous polymer-filled chromatography resin beads through one or more screens having openings from about 50 μm to about 200 μm.

3. The method of claim 1 , further comprising washing the insoluble porous polymer-filled chromatography resin beads.

4. The method of claim 1 , wherein the melted polymer is agarose and the agarose is in a concentration from about 0.5% to about 8% weight by volume.

5. The method of claim 1 , wherein the chromatography resin is a macroporous resin.

6. The method of claim 5 , wherein the macroporous resin is a hydroxyapatite microsphere.

7. The method of claim 5 , wherein the macroporous resin comprises acrylamide, methacrylate, polystyrene, or silica.

8. The method of claim 7 , wherein the macroporous resin comprises a copolymer of 3-allyloxy-1,2-propanediol and vinyl pyrrolidinone crosslinked with N,N′-methylenebisacrylamide.

9. The method of claim 7 , wherein the macroporous resin comprises glycidyl methacrylate and diethylene glycol dimethacrylate.

10. The method of claim 1 , wherein the melted polymer is at about 100° C.

11. The method of claim 1 , wherein atomizing the solution comprises surrounding the solution emerging from a nozzle with a stream of air.

12. The method of claim 11 , wherein a temperature of the stream of air is about 20° C. to about 90° C.

13. The method of claim 11 , wherein a flow rate of the.

14. The method of claim 1 , wherein a temperature of the water bath is about 4° C. to about 40° C.

15. A method of performing chromatography, the method comprising

contacting a sample comprising a target molecule to an insoluble porous polymer-filled chromatography resin prepared by the process of claim 1 under conditions such that the target molecule is not captured by the insoluble porous polymer-filled chromatography resin; and

collecting the target molecule from the insoluble porous polymer-filled chromatography resin.

16. The method of claim 15 , wherein the sample comprises a contaminant that is captured by the insoluble porous polymer-filled chromatography resin.

17. The method of claim 15 , wherein the target molecule is a protein-nanoparticle conjugate and the contaminant is free protein.

18. The method of claim 15 , wherein the sample comprises a protein-nanoparticle conjugate, free protein, and a buffer.

19. The method of claim 18 , wherein the sample further comprises a surfactant.

20. The method of claim 19 , wherein the surfactant is polyalkylene glycol.

21. The method of claim 20 , wherein the surfactant is Pluronic F-68.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 18, 2022
From: XU, JAMES WEI; LIAO, JIALI; BELISLE, CHRISTOPHER; SONG, FANG; YUAN, HAIHUI; YOU, JUAN; CAO, WENLI; BAO, XIAOZHONG
To: BIO-RAD LABORATORIES, INC.
Reel/Frame 060849/0059 →
Continuity (1)
Related Publication 20230087779A1 · Mar 23, 2023
References Cited (67)
US 4551245A · Ramsden et al. · 1985 [cited by applicant]
US 4971833A · Larsson et al. · 1990 [cited by applicant]
US 6368703B1 · Johnson · 2002 [cited by applicant]
US 6423666B1 · Liao et al. · 2002 [cited by applicant]
US 6613234B2 · Voute et al. · 2003 [cited by applicant]
US 6972090B2 · Boschetti et al. · 2005 [cited by applicant]
US 7678269B2 · Cheng et al. · 2010 [cited by applicant]
US 8093373B2 · Alstine et al. · 2012 [cited by applicant]
US 8182831B2 · Lin et al. · 2012 [cited by applicant]
US 8574437B2 · Bergstrom et al. · 2013 [cited by applicant]
US 8814936B2 · Draenert · 2014 [cited by applicant]
US 9155980B2 · Glad et al. · 2015 [cited by applicant]
US 9259729B2 · Bergstrom et al. · 2016 [cited by applicant]
US 9278297B2 · Bergstrom et al. · 2016 [cited by applicant]
US 9382473B2 · Chiu · 2016 [cited by applicant]
US 9383299B2 · Kunkel et al. · 2016 [cited by applicant]
US 10814305B2 · Liao et al. · 2020 [cited by applicant]
US 10934366B2 · Liao et al. · 2021 [cited by applicant]
US 20020104801A1 · Voute et al. · 2002 [cited by applicant]
US 20030125529A1 · Boschetti et al. · 2003 [cited by applicant]
US 20030166869A1 · Vedantham · 2003 [cited by applicant]
US 20060246524A1 · Bauer · 2006 [cited by applicant]
US 20070072303A1 · Arpaia · 2007 [cited by applicant]
US 20110045574A1 · Bergstrom et al. · 2011 [cited by applicant]
US 20120141497A1 · Gallo · 2012 [cited by applicant]
US 20130034854A1 · Ashworth-Sharpe · 2013 [cited by applicant]
US 20150377869A1 · Berkelman · 2015 [cited by applicant]
US 20180085735A1 · Liao et al. · 2018 [cited by applicant]
US 20210179736A1 · Liao et al. · 2021 [cited by applicant]
BR PI07029349A2 · 2009 [cited by applicant]
CN 103923355A · 2014 [cited by applicant]
CN 103923355B · 2016 [cited by applicant]
CN 107042093A · 2017 [cited by applicant]
CN 109803736A · 2019 [cited by applicant]
EP 0337123A1 · 1989 [cited by applicant]
EP 1131383B1 · 2003 [cited by applicant]
EP 1071500B1 · 2005 [cited by applicant]
GB 2324601A · 1998 [cited by applicant]
JP 6316046A · 1988 [cited by applicant]
JP 2002510541 · 2002 [cited by applicant]
JP 2004099433A · 2004 [cited by applicant]
JP 2010132779A · 2010 [cited by applicant]
WO 0012618A1 · 2000 [cited by applicant]
WO 2007008250A2 · 2007 [cited by applicant]
WO 2010051360A1 · 2010 [cited by applicant]
WO 2013096831A1 · 2013 [cited by applicant]
WO 2015137860A1 · 2015 [cited by applicant]
WO 2017174422A1 · 2017 [cited by applicant]
WO 2018181925A1 · 2018 [cited by applicant]
WO 2019173731A1 · 2019 [cited by applicant]
Extended European Search Report in EP Appln. 20919634.4 mailed Sep. 22, 2023; 14 pages. [cited by applicant]
International Search Report and Written Opinion in PCT/CN2020/075807 mailed Oct. 26, 2020; 9 pages. [cited by applicant]
Basargan, T. et al.; “Spray-dried mesoporous hydroxyapatite-chitosan biocomposites”; [cited by applicant]
Wang, A.J. et al.; “Effect of process parameters on the performance of spray dried hydroxyapatite microspheres”; [cited by applicant]
“Capto Core 700”; GE Healthcare Life Sciences; Data file: 28-9983-07 AA, Multimodal chromatography; Mar. 2012; pp. 1-4. [cited by applicant]
“BioSepra HA Ultrogel”; Product Insert; Insert No. 292200; PALL Life Sciences; Mar. 2007; 2 pages. [cited by applicant]
Pall Life Sciences, “BioSepra HA Ultrogel: Product Note”, [available online at https:/lshop.pall.com/INTERSHOP/web/WFS/PALL-PALLUS-Site/en_US/-/USDNiewProductAttachment-OpenFile?LocaleId=&DirectoryPath=pdfs%2FBiopharmac… [cited by applicant]
Kolanthai, et al., “Synthesis of nanosized hydroxyapatite/agarose powders for bone filler and drug delivery application”, Materials Today Communications, vol. 8, May 16, 2016, pp. 31-40. [cited by applicant]
PCT/US2017/053217, “International Search Report and Written Opinion”, Dec. 11, 2017, 9 pages. [cited by applicant]
“BioSepra HA Ultrogel: Process Proteomics Product Note” (Oct. 2002), BioSepra S.A., Ciphergen BioSepra Process Division, pp. 1-4. [cited by applicant]
“Purification of influenza A/H1N1 using Capto Core 700,” Data file: 29-0003-34 AA, GE Healthcare Bio-Sciences AB, (Mar. 2012), pp. 1-8. [cited by applicant]
Zhang, Yue et al., “Light-induced Crosslinkable Semiconducting Polymer Dots,” NIH Public Access, Chemical Science, (Mar. 2015), vol. 6(3), pp. 2102-2109. [cited by applicant]
Bio-Rad Laboratories, Inc.; “CHT Ceramic Hydroxyapatite”; Bulletin 5667, Rev. B; Jul. 2013; 4 pages. [cited by applicant]
Machine Translation of Wang CN 103923355. [cited by applicant]
Extended European Search Report in EP Appln. 17857257.4 mailed Apr. 2, 2020; 13 pages. [cited by applicant]
Fisher Scientific; “Centrifugation Theory”; Accessed Jun. 16, 2020; 7 pages. [cited by applicant]
“Capto Core 400 Capto-Core 700”; GE Healthcare Life Sciences; Product Info Sheet; 2012-2018; 8 pages. [cited by applicant]